Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Wrinkle In NDI Debate: Supplement Ingredients Used As Drugs Outside US

This article was originally published in The Tan Sheet

Executive Summary

Senator McCaskill asks FDA to halt sales of supplements containing vinpocetine and picamilion after research, led by an advocate for tighter regulation of supplement manufacturing, shows the ingredients are not derived from natural sources but are synthetic and used as drugs in other countries.

Advertisement

Related Content

FDA Opens Extra-Regulatory Enforcement Door On Vinpocetine – CRN, NPA
Hatch Questions FDA Motive, Process In Proposed Vinpocetine Ban
FDA Finds Ingredient's IND Past After Signing Off For Supplement Use
Supplement NDI Draft Guidance Discussions Snagged On Basic Criteria
FDA Revision Of NDI Draft Guidance Starts With Grandfathered List

Topics

Advertisement
UsernamePublicRestriction

Register

PS107950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel